Wall Street analysts expect GlaxoSmithKline plc (NYSE:GSK) to announce earnings per share (EPS) of $0.65 for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for GlaxoSmithKline’s earnings, with the lowest EPS estimate coming in at $0.58 and the highest estimate coming in at $0.72. GlaxoSmithKline also reported earnings per share of $0.65 during the same quarter last year. The business is expected to issue its next quarterly earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that GlaxoSmithKline will report full-year earnings of $2.90 per share for the current fiscal year, with EPS estimates ranging from $2.76 to $3.00. For the next fiscal year, analysts forecast that the firm will report earnings of $2.80 per share, with EPS estimates ranging from $2.72 to $3.01. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow GlaxoSmithKline.

GSK has been the topic of several analyst reports. UBS Group raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $35.04 to $35.85 in a research report on Monday, November 27th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. ValuEngine cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Morgan Stanley cut shares of GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. Finally, TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $38.17.

In other news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.00% of the stock is currently owned by corporate insiders.

Several hedge funds have recently modified their holdings of GSK. Principal Financial Group Inc. bought a new stake in shares of GlaxoSmithKline in the 2nd quarter valued at about $602,000. Pacad Investment Ltd. raised its holdings in shares of GlaxoSmithKline by 111.4% in the 2nd quarter. Pacad Investment Ltd. now owns 9,300 shares of the pharmaceutical company’s stock valued at $401,000 after purchasing an additional 4,900 shares during the period. Eagle Asset Management Inc. raised its holdings in shares of GlaxoSmithKline by 10.9% in the 2nd quarter. Eagle Asset Management Inc. now owns 11,162 shares of the pharmaceutical company’s stock valued at $481,000 after purchasing an additional 1,094 shares during the period. Atlantic Trust Group LLC raised its holdings in shares of GlaxoSmithKline by 13.2% in the 2nd quarter. Atlantic Trust Group LLC now owns 58,006 shares of the pharmaceutical company’s stock valued at $2,501,000 after purchasing an additional 6,770 shares during the period. Finally, Private Advisor Group LLC raised its holdings in shares of GlaxoSmithKline by 1.5% in the 2nd quarter. Private Advisor Group LLC now owns 72,764 shares of the pharmaceutical company’s stock valued at $3,072,000 after purchasing an additional 1,055 shares during the period. 9.81% of the stock is currently owned by institutional investors.

Shares of GlaxoSmithKline (NYSE:GSK) traded up $0.65 during trading hours on Friday, reaching $37.51. 7,250,000 shares of the company’s stock traded hands, compared to its average volume of 5,170,000. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. GlaxoSmithKline has a 52-week low of $34.52 and a 52-week high of $44.53. The company has a market cap of $91,340.00, a PE ratio of 29.08, a PEG ratio of 2.11 and a beta of 0.97.

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a $0.5037 dividend. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.37%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is presently 154.26%.

COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/06/brokerages-anticipate-glaxosmithkline-plc-gsk-will-post-earnings-of-0-65-per-share.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Get a free copy of the Zacks research report on GlaxoSmithKline (GSK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.